OBJECTIVE: Assess whether the presence of mucosal eosinophilia correlates with surgical outcomes in patients with chronic rhinosinusitis. STUDY DESIGN: Prospective cohort. SETTING: Tertiary medical center. SUBJECTS AND METHODS: Adult patients with chronic rhinosinusitis were prospectively enrolled, and demographic data and medical comorbidities were recorded. Preoperative quality of life (QOL) was measured by the Chronic Sinusitis Survey (CSS), Rhinosinusitis Disability Index (RSDI), and Short Form-36 General Health Survey (SF-36). Sinus mucosal specimens were collected at the time of surgery and the degree of eosinophilia quantified. Postoperative QOL was measured, and differences in QOL improvement were compared between those with and without eosinophilia. RESULTS: A total of 102 patients had both histopathological and QOL outcome data available for review. Follow-up averaged 16.5 months. Patients with eosinophilia showed significantly less improvement in the RSDI total (17.9 vs 25.0; P ϭ 0.044), RSDI functional (5.7 vs 8.8; general health subscale; P ϭ 0.018), CSS medication (3.6 vs 17.3; P ϭ 0.013), SF-36 general health (0.6 vs 9.6; P ϭ 0.008), SF-36 physical role (16.1 vs 34.7; P ϭ 0.036), and SF-36 vitality (11.9 vs 21.2; P ϭ 0.034) scales than those without eosinophilia. The greatest improvement in QOL was seen in patients without eosinophilia or polyps, with the least improvement seen in those with eosinophilia but without polyps. CONCLUSION: The presence of mucosal eosinophilia at the time of surgery consistently predicted less improvement in both disease-specific and general QOL compared with patients without eosinophilia. The impact of eosinophilia on outcomes was greatest for patients without nasal polyposis, a group that demonstrated the least improvement in QOL measures.
N umerous authors and consensus groups have argued the merits of various classification schemes for chronic rhinosinusitis (CRS). Some have proposed including the presence or absence of eosinophilic inflammation as a de-fining feature. 1 We recently published histological findings from a cohort of patients with CRS undergoing endoscopic sinus surgery (ESS). 2 Our data show that mucosal eosinophilia correlates with baseline objective disease severity as defined by CT, endoscopy, and olfactory testing. Although numerous other histological markers of inflammation were present, none showed similar correlations.
Despite predicting worse objective disease severity, the presence of mucosal eosinophilia did not correlate with baseline disease-specific or general quality of life (QOL). The question remains whether knowledge of eosinophilic status provides useful long-term prognostic information. The primary goal of the current study is to assess whether the presence of mucosal eosinophilia correlates with longterm surgical outcomes in patients with chronic rhinosinusitis.
Methods

Study Population
Adult (Ն18 years) participants were prospectively recruited from a tertiary care center over a three-year period with approval of the Oregon Health and Science University Institutional Review Board. All patients had a diagnosis of CRS based on the Rhinosinusitis Task Force criteria endorsed by the American Academy of Otolaryngology Head and Neck Surgery. 3 Patients were enrolled at the time they had failed medical management and had elected to undergo ESS. Medical management included at least a prolonged course of broad-spectrum or culture-directed antibiotics for four weeks and a trial of topical nasal corticosteroid spray. All patients were on medical cointerventions at the time of surgery to provide ongoing medical management of their disease and to prepare their sinonasal mucosa for surgery. These cointerventions included an oral prednisone taper beginning seven days prior to surgery (30 mg/day for four days, then 20 mg/day for three days) and oral antibiotics. Patients were also instructed to continue topical nasal steroid application and allergy therapy.
Preoperative demographic and medical history was obtained from both the patient and the medical record and included age, sex, history of prior sinus surgery, nasal polyposis, asthma, allergic rhinitis (confirmed by either skin prick testing or modified radioallergic sorbent testing), and acetylsalicylic acid intolerance. CT scans in the coronal plane were obtained by the physician principal investigator preoperatively and evaluated by using the Lund-Mackay CT scoring system (0-24 point scale). 4 Rigid sinonasal endoscopy was performed preoperatively and quantified by using the endoscopic scoring system outlined by Lund and Kennedy (0-20 point scale). 5 The Smell Identification Test (SIT; Sensonics, Inc, Haddon Heights, NJ) was administered as an objective measure of olfactory function (0-40 point scale).
QOL Evaluation
Consenting patients were asked to complete two diseasespecific QOL instruments, the Rhinosinusitis Disability Index (RSDI) and the Chronic Sinusitis Survey (CSS), and one general QOL instrument, the 36-Item Short Form Health Survey (SF-36), both prior to and after surgery. [6] [7] [8] The RSDI measures rhinological health by way of 30 questions separated by physical, functional, and emotional subscales (0-120 point range). The CSS is an eight-week duration monitor of sinusitis-specific outcomes composed of six questions in each symptom and medication subscale (0-100 point range). The SF-36 is a multipurpose general health survey that measures eight domains of health: physical functioning, role limitations due to physical health, bodily pain, general health perceptions, vitality, social functioning, role limitations due to emotional problems, and mental health (0-100 point range). Higher scores on the RSDI represent overall higher impact and worse disease severity, whereas higher scores on the CSS and SF-36 domains represent lower impact and lesser disease severity. A research coordinator administered all survey instruments pre-and postoperatively during the normal delivery of care for each patient. Data collected at the last postoperative clinic visit during the study period was considered for outcome analyses. The principal investigator was blinded to all QOL responses for the study duration.
Histological Evaluation
Sinus mucosal tissue was collected from the ethmoid cavity at the time of surgery. These specimens represented the mucosa removed as necessary to complete a standard endoscopic ethmoidectomy. Standard pathological laboratory techniques were used to prepare all samples. Tissue specimens were promptly immersed in 10 percent neutral buffered formalin (NBF) and fixed for a minimum of four hours. The specimens were grossly examined and submitted into a plastic mesh cassette in toto and again immersed in NBF for an additional three to 12 hours. Following a three-minute cold water rinse, the tissue cassette was immersed in an acid decalcification solution (Decal Stat, Tallman, NY) for eight hours and again rinsed with cold water for three minutes. Tissue cassettes then underwent a 12-hour cycle in an automated processor (Sakura VIP; Sakura Finetek USA, Torrance, CA) prior to paraffin embedding (Sakura Tissue-Tec; Sakura Finetek USA). Histological sections of 4 were prepared on a microtome, and the slide was placed in an automated stainer and glass coverslipper. The hematoxylineosin (H&E)-stained slides were then banked for review.
Microscopic review was performed by a single boardcertified surgical pathologist using a binocular microscope (Leica DM2000; Leica Microsystems Inc, Bannockburn, IL) with a graduated reticle mounted within one of the eyepiece objectives (ϫ10, 10 mm with 1.0 mm divisions). At ϫ400 power the reticle field is 250 ϫ 250 , yielding an area of approximately 0.13 square millimeters (mm 2 ). Histological review was performed to assess the number of mucosal eosinophils present. Eosinophils were quantified in the foci of the densest cellular infiltrate to ensure that patients were consistently classified on the basis of the area of greatest inflammation. Eosinophil count was recorded in each reticle field at ϫ400 power and reported as absolute number per high-power field (HPF). The pathological review was done in a blinded fashion with regard to all clinical data.
Statistical Analysis
All histological data and QOL responses were compiled and recorded on standardized clinical research forms. Statistical analyses were completed by using SPSS v16.0 statistical software (SPSS, Inc, Chicago, IL). Change in QOL scores was calculated for all patients from preoperative to postoperative time points. Differences in QOL improvement were then compared between those with and without mucosal eosinophilia by using independent t tests for parametric and Mann-Whitney U tests for nonparametric data.
Optimal Eosinophilia Cut Point
Because specific criteria for what constitutes clinically relevant mucosal eosinophilia remain undefined, a combination of methods was utilized to identify the optimal cut point for dichotomizing subjects into those with and those without eosinophilia. These methods included the graphical examination of nonparametric distribution for evidence of an eosinophilia threshold effect and the minimum P value approach. With the focus on the RSDI total, six cut points were compared: Ͼ1 eosinophil/HPF, Ͼ5 eosinophils/HPF, Ͼ10 eosinophils/HPF, Ͼ50 eosinophils/HPF, Ͼ100 eosinophils/HPF, and Ͼ250 eosinophils/HPF. The optimal cut point was then defined as the candidate cut point with the largest absolute difference in disease-specific QOL change scores (postoperative minus preoperative) and smallest corresponding P value. Patients with an eosinophil count above the cut point were considered to have mucosal eosinophilia for the purposes of this study.
CRS Subtype Comparison
Finally, patients were classified into four subtypes of CRS on the basis of the clinical presence of nasal polyps and the histological presence of mucosal eosinophilia as defined by the optimal cut point determination: Eosinophilic CRS with Nasal Polyposis (ECRSwNP), Non-Eosinophilic CRS with Nasal Polyposis (CRSwNP), Eosinophilic CRS without Nasal Polyposis (ECRSsNP), and Non-Eosinophilic CRS with-out Nasal Polyposis (CRSsNP). Differences in QOL outcomes between these subtypes were compared by using Kruskal-Wallis and Mann-Whitney U tests where appropriate. A P value Յ 0.05 was considered statistically significant for all analyses. Means and SDs (Ϯ) are reported.
Results
Baseline Findings
A total of 147 patients were enrolled into the study at baseline. Of this group, 102 had both histopathological and QOL outcome data available for analyses. For the 45 patients not included in the final analyses (lost to follow-up), a baseline comparison of disease-severity (CT, endoscopy, olfaction, and QOL scores) revealed no differences when compared with the final cohort. The demographic and comorbidity characteristics of the cohort are shown in Table 1 , along with CT, endoscopy, and SIT scores. The average age was 46.7 years (range 23-79 years), with 51 percent males and 49 percent females. Overall follow-up averaged 16.5 months (range 4-37 months). Overall, 79.4 percent of patients had Ͼ1 eosinophil/HPF, 51.0 percent had Ͼ5 eosinophils/HPF, 47.1 percent had Ͼ10 eosinophils/ HPF, 28.4 percent had Ͼ50 eosinophils/HPF, 22.5 percent had Ͼ100 eosinophils/HPF, and 11.8 percent had Ͼ250 eosinophils/HPF (Fig 1) .
Eosinophilia Cut Point
The change in RSDI total scores after surgery (postoperative minus preoperative) for patients above and below each eosinophilia cut point are shown in Table 2 . Also shown is the absolute difference in RSDI change score between those 
Figure 1
Frequency distribution and range of absolute eosinophil counts for study subjects (n ϭ 102).
above and below the specific cut point. The greatest difference in outcome was seen when using a cut point Ն10 eosinophils/HPF. Patients with Ն10 eosinophils/HPF averaged 7.1 points less improvement on the RSDI total scale than those with Ͻ10 eosinophils/HPF. This difference also had the greatest statistical significance at P Ͻ 0.04. Therefore, a value of Ն10 eosinophils/HPF was defined as the optimal cut point and referred to as "mucosal eosinophilia" for the remainder of the analyses.
QOL Outcomes
A comparison of disease-specific and general health QOL scores between those with and without eosinophilia are shown in Tables 3 and 4 . As in our prior study, no baseline differences were seen for any QOL instrument between patients with and without eosinophilia on the RSDI, CSS, or SF-36. Statistically significant postoperative improvement (postoperative minus preoperative) was seen across most QOL indices for patients whether or not they had eosino-philia. However, in comparisons of the level of improvement, there was a global tendency for those with eosinophilia to show less improvement in QOL than those without eosinophilia. Patients with eosinophilia showed significantly less improvement in the RSDI total (17.9 vs 25.0; P ϭ 0.044), RSDI functional (5.7 vs 8.8; P ϭ 0.018), CSS medication (3.6 vs 17.3; P ϭ 0.013), SF-36 general health (0.6 vs 9.6; P ϭ 0.008), SF-36 physical role (16.1 vs 34.7; P ϭ 0.036), and SF-36 vitality (11.9 vs 21.2; P ϭ 0.034) scales than those without eosinophilia. In addition, patients with eosinophilia also showed a similar trend (P Ͻ 0.10) toward worse improvement in the CSS total, RSDI emotional, SF-36 physical functioning, SF-36 social functioning, and SF-36 mental health scales, although these did not reach our defined significance level. CRS subtype outcomes. Patients were classified into four subtypes on the basis of the presence or absence of nasal polyposis and mucosal eosinophilia. Most patients were classified as CRSsNP (n ϭ 38), followed by 
Discussion
Prior studies investigating surgical outcomes for CRS have shown significant improvements in mean symptom scores and QOL. 9, 10 However, these studies also reveal that significant variability exists as to the degree of improvement in individual patients. Past studies have highlighted various demographic factors, clinical factors, and comorbidities, which explain some differences in disease severity and outcomes after ESS. 11, 12 This study defines a histopathological finding (mucosal eosinophilia) that, if present, predicts less long-term QOL improvement after ESS. Numerous authors have argued the merits of a clinical classification scheme that includes the presence or absence of nasal polyposis and mucosal eosinophilia as defining features. 1 To be clinically useful, the knowledge of mucosal eosinophilic status would either provide certain prognostic information about disease severity/outcome or allow for specific tailored treatments. This study supports classifying patients on the basis of the presence or absence of mucosal eosinophilia because it shows that the knowledge of mucosal eosinophilic status provides important prognostic information about long-term outcomes. Perhaps what is most interesting is that the greatest impact of eosinophilia on outcomes was seen in those patients without nasal polyposis. In CRS patients without nasal polyps, the presence of eosinophilia (Ն10 eosinophils/HPF) predicted the least improvement in QOL compared with those without eosino-philia, who experienced the greatest improvement. Interestingly, on the basis of clinical presentation alone, these patients might be otherwise indistinguishable.
The presence or absence of mucosal eosinophilia did not seem to affect QOL improvement for patients with polyposis in this study cohort. Patients with polyps have long been thought of as a separate and distinct subgroup of CRS. Prior studies have shown that the physical presence of polyps filling the nasal cavity leads to worse objective findings on CT and endoscopy compared those of the average CRS patient. Additionally, patients with polyps typically complain of nasal obstruction as the dominant symptom with a lower incidence of symptoms such as facial pain/pressure or nasal discharge. The physical removal of polyps as done during ESS would be expected to dramatically improve nasal obstruction and thus improve the dominant symptom contributing to QOL decline. This would be true regardless of whether or not mucosal eosinophilia is present. The tendency for polyps to recur is well established but may take many years to manifest in symptomatic decline. The follow-up for this study (16.5 month average) may not have been long enough to detect a difference in polyp recurrence rates on the basis of eosinophilia, if one in fact exists. Further research is necessary with longer-term outcomes to fully address this issue.
When analyzing outcomes research, one must make a distinction between statistically significant findings and those that are also clinically relevant to the individual patient or physician. Generally speaking, QOL changes become clinically meaningful when they approximate one half of the SD of the baseline QOL value. This seemingly arbitrary definition of clinical relevance has been validated across many disease-specific and general QOL instruments. 13 In this study, clinically significant differences were seen in the CRS subtype comparisons for each QOL instrument studied. For example, patients without polyps or eosinophilia (CRSsNP) improved by 26.4 points on the RSDI total versus only 13.9 for those without polyps but with eosinophilia (ECRSsNP), a difference of 12.5 points (½SD ϭ 9.0 points; 0-120 scale). The difference between these two subtypes was 17.2 points on the CSS total scale (½SD ϭ 10.0 points; 0-100 scale) and 35.8 points on the CSS medication scale (½SD ϭ 13.3 points; 0-100 scale). With regard to the SF-36, the minimal clinically important difference has been established at 10 to 12.5 points for diseases such as asthma, congestive obstructive pulmonary disease, and coronary artery disease. 14 ECRSsNP patients had 17.5 points less improvement on the SF-36 general health scale than patients classified as CRSsNP, a level well above the threshold of clinical relevance.
If mucosal eosinophilia is going to be used for classification purposes, criteria must be outlined as to what exactly defines the condition. In our earlier work we used a cut point Ͼ5 eosinophils/HPF to define clinically relevant mucosal eosinophilia. 2 This was based in part on a prior study that suggested that Ͼ5 eosinophils/HPF was associated with in vivo evidence of eosinophil activation. 15 In the current study, we explored numerous cut points to better understand the impact of eosinophilia on outcomes. The greatest impact on QOL outcomes was seen when the mucosal infiltrate reached Ͼ10 eosinophils/HPF. Interestingly, there did appear to be a threshold effect at, or near, 10 eosinophils/HPF. Above this level, increasing density of eosinophils did not result in progressively more effect on QOL. Future research is needed to fully establish the optimal cut point that identifies clinically relevant mucosal eosinophilia.
The results of this study have both research and clinical implications. Clinical outcomes research on CRS often seeks to investigate the pertinent factors that predict treatment response. Prior studies have shown that patient factors identifiable at presentation can impact treatment outcomes, such as sex and medical comorbidities. 11, 12 This study shows that microscopic pathological factors also provide predictive information. Future outcomes studies will need to evaluate differences on the molecular and genetic levels to fully explore the root causes of patient variability. From a clinical standpoint, the data from this study highlight the importance of detailed surgical pathology reports, especially with respect to mucosal eosinophilia. The technique used in this study to quantify eosinophilia should translate well to the clinical realm because it utilizes standard H&E stains and has been shown to be highly reproducible. 16 The strengths of this study include the sample size, the length of follow-up, the prospective nature of data collection, and the rigorous methodology used to quantify eosin- ophilia. Additionally, both disease-specific and general QOL were assessed by using previously validated instruments. There are, however, caveats to consider in the interpretation of these findings. Mean Lund-Mackay CT scores on this cohort were 13.0, suggesting moderate to severe inflammatory mucosal disease. Therefore, patients in this study were on medical cointerventions that included topical nasal steroids and preoperative oral steroids to reduce inflammatory mucosal disease and prepare the sinonasal mucosa for surgery. This preoperative regimen has the potential to impact mucosal inflammation, including the degree of mucosal eosinophilia. Studies evaluating patients with CRS who are not exposed to medical cointerventions at the time of mucosal biopsy would assist in determining medication effect on mucosal eosinophilia. Finally, the cohort was enrolled and studied at a tertiary rhinology center, and the results may not be generalizable to the entire population undergoing sinus surgery. Larger multicenter-and community-based studies will be necessary to validate the results.
Conclusion
Many feel that patients with eosinophilic CRS represent a unique subgroup that is especially refractory to medical and surgical intervention. 17 However, few studies have sought to prospectively evaluate the clinical relevance of mucosal eosinophilia with regard to treatment outcomes. This study evaluated the relationship between mucosal eosinophilia at baseline and QOL outcomes after sinus surgery. The presence of mucosal eosinophilia (Ͼ10 eosinophils/HPF) at the time of ESS consistently predicted less improvement in both diseasespecific and general QOL compared with patients without eosinophilia. The impact of eosinophilia on outcomes was greatest for CRS patients without nasal polyposis, a group that demonstrated the least improvement in QOL measures.
